Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 Marzo 2024 - 4:10PM
Celldex Therapeutics, Inc. (“Celldex” or the “Company”)
(Nasdaq: CLDX) today announced the closing of its previously
announced underwritten public offering of 9,798,000 shares of its
common stock, which includes the exercise in full by the
underwriters of their option to purchase an additional 1,278,000
shares of common stock at a public offering price of $47.00
per share. All of the shares sold in the offering were sold by
Celldex. The gross proceeds to Celldex from this offering were
approximately $460.5 million, excluding underwriting discounts and
commissions and other offering-related expenses.
Leerink Partners, TD Cowen, Guggenheim Securities and Cantor
acted as the joint bookrunning managers for the offering. LifeSci
Capital and H.C. Wainwright & Co. acted as co-lead managers for
the offering.
The securities described above were offered and sold by Celldex
pursuant to a prospectus supplement and an accompanying base
prospectus forming part of a shelf registration statement on Form
S-3 (File No. 333-275300), which was previously filed with
the Securities and Exchange Commission (“SEC”) and became
automatically effective on November 3, 2023, and are available on
the SEC’s website located
at http://www.sec.gov. Copies of the
prospectus supplement and the accompanying base prospectus may be
obtained for free by contacting Leerink Partners LLC, Syndicate
Department, 53 State Street, 40th Floor, Boston, MA 02109, or by
telephone at (800) 808-7525 ext. 6105 or by email at
syndicate@leerink.com; or Cowen and Company, LLC, 599 Lexington
Avenue, New York, NY 10022, by email at Prospectus_ECM@cowen.com or
by telephone at (833) 297-2926.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the
science at the intersection of mast cell biology and the
development of transformative therapeutics for patients. Our
pipeline includes antibody-based therapeutics which have the
ability to engage the human immune system and/or directly affect
critical pathways to improve the lives of patients with severe
inflammatory, allergic, autoimmune and other devastating
diseases.
Forward Looking Statement
This release contains “forward-looking statements” made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements are typically preceded by
words such as “believes,” “expects,” “anticipates,” “intends,”
“will,” “may,” “should,” or similar expressions. These
forward-looking statements reflect management’s current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct or that those goals
will be achieved, and you should be aware that actual results could
differ materially from those contained in the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, risks
associated with market conditions. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the Company’s business in general, please
refer to the Company’s prospectus supplement to be filed with the
SEC, and the documents incorporated by reference therein, including
the Company’s Form 10-K for the year ended December 31, 2023.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Sarah CavanaughSenior Vice President, Corporate Affairs &
AdministrationCelldex Therapeutics, Inc.(508)
864-8337scavanaugh@celldex.com
Patrick TillMeru Advisors(484)
788-8560ptill@meruadvisors.com
Grafico Azioni Celldex Therapeutics (NASDAQ:CLDX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Celldex Therapeutics (NASDAQ:CLDX)
Storico
Da Mag 2023 a Mag 2024